Application Acceleration on FPGAs with OmpSs@FPGA

© 2019 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes,creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works.OmpSs@FPGA is the flavor of OmpSs that allows offloading application functionality to FPGAs. Similarly to OpenMP, it is based on compiler directives. While the OpenMP specification also includes support for heterogeneous execution, we use OmpSs and OmpSs@FPGA as prototype implementation to develop new ideas for OpenMP. OmpSs@FPGA implements the tasking model with runtime support to automatically exploit all SMP and FPGA resources available in the execution platform. In this paper, we present the OmpSs@FPGA ecosystem, based on the Mercurium compiler and the Nanos++ runtime system. We show how the applications are transformed to run on the SMP cores and the FPGA. The application kernels defined as tasks to be accelerated, using the OmpSs directives are: 1) transformed by the compiler into kernels connected with the proper synchronization and communication ports, 2) extracted to intermediate files, 3) compiled through the FPGA vendor HLS tool, and 4) used to configure the FPGA. Our Nanos++ runtime system schedules the application tasks on the platform, being able to use the SMP cores and the FPGA accelerators at the same time. We present the evaluation of the OmpSs@FPGA environment with the Matrix Multiplication, Cholesky and N-Body benchmarks, showing the internal details of the execution, and the performance obtained on a Zynq Ultrascale+ MPSoC (up to 128x). The source code uses OmpSs@FPGA annotations and different Vivado HLS optimization directives are applied for acceleration.This work is partially supported by the European Union H2020 program through the EuroEXA project (grant 754337), and HiPEAC (GA 687698), by the Spanish Government through Programa Severo Ochoa (SEV-2015- 0493), by the Spanish Ministry of Science and Technology (TIN2015-65316-P) and the Departament d’Innovació Universitats i Empresa de la Generalitat de Catalunya, under project MPEXPAR: Models de Programació i Entorns d’Execució Paral·lels (2014-SGR-1051).Peer ReviewedPostprint (author's final draft

Predictors, pathological characteristics and outcomes of bladder recurrences following nephroureterectomy

Objetivos: Analizar las variables predictoras de recidiva vesical (RV) tras nefroureterectomía(NU) por tumor de tracto urinario superior (TTUS), así como sus características patológicas,evolución y repercusión en supervivencia. Material y métodos: Estudio retrospectivo de 117 pacientes sometidos a NU laparoscópica por TTUS entre 2007-2012 en nuestro centro. Los posibles factores predictores de RV se analizaron mediante regresión de Cox y para el estudio de supervivencia se utilizaron las curvas de Kaplan-Meier.Resultados: Fueron 85 hombres (73%) y 32 mujeres (27%) con una edad media de 70 años. Tras un seguimiento medio de 26 meses, 23 presentaron RV (19,6%). En el análisis multivariante, el género (p = 0,003; HR mujer 3,8) y la localización del TTUS en uréter distal (p = 0,002; HR 4,8) fueron predictores independientes de RV. La mediana de tiempo hasta la RV fue de 8 meses. Quince pacientes presentaron una RV no músculo-invasiva (65,2%) y 8 músculo-invasiva (34,8%). Todas las RV excepto 2, aparecieron durante los primeros 2 años. Cinco casos con RV no músculo-invasiva presentaron nueva RV. Seispacientes con RV músculo-invasiva murieron sin poderse definir si fue por tumor vesical o de vías. La aparición de RV no mostró repercusión en la supervivencia de los pacientes con TTUS. Conclusiones: El género (mujer) y la localización del TTUS (uréter distal) son factores predic-tores de RV tras NU. Pacientes con estas características podrían beneficiarse de tratamientoadyuvante intravesical y de un seguimiento más estricto. La aparición de RV no tiene impacto en la supervivencia de los pacientes con TTUS. OBJECTIVES: To analyze the predictors for bladder recurrence (BR) after nephroureterectomy (NU) for upper urinary tract tumors (UUTT), as well as its pathological characteristics, outcomes and impact on survival. MATERIAL AND METHODS: Retrospective study of 117 patients who underwent laparoscopic nephroureterectomy by UUTT between 2007-2012 at our center. The potential predictors for BR were analyzed using Cox regression; Kaplan-Meier curves were employed to study survival. RESULTS: The sample was composed of 85 men (73%) and 32 women (27%), with a mean age of 70 years. After a mean follow-up of 26 months, 23 patients presented BR (19.6%). In the multivariate analysis, sex (p=.003; HR [female], 3.8) and the location of the UUTT in the distal ureter (p=.002; HR, 4.8) were independent predictors for BR. The median time to BR was 8 months. Fifteen patients presented a nonmuscle-invasive BR (65.2%), and 8 presented a muscle-invasive BR (34.8%). All BRs, except for 2, appeared during the first 2 years. Five cases with nonmuscle-invasive BR presented a new BR. Six patients with muscle-invasive BR died before it could be determined whether cause of death was the BR or an UUTT relapse. The onset of BR showed no repercussion on the survival of patients with UUTT. CONCLUSIONS: Sex (female) and the location of the UUTT (distal ureter) are predictors for BR after NU. Patients with these characteristics might benefit from adjuvant intravesical treatment and closer monitoring. The onset for RV has no impact on the survival of patients with UUTT

Logística de distribució, febrer 2008

Material docent de la Universitat Oberta de Catalunya.Material docente de la "Universitat Oberta de Catalunya".Learning material of the "Universitat Oberta de Catalunya"

Sistemas de distribución, febrero 2013

Recurs d'aprenentatge de la Universitat Oberta de Catalunya.Recurso de aprendizaje de la "Universitat Oberta de Catalunya".Learning material of the "Universitat Oberta de Catalunya"

Logística de distribució, febrer 2008

Material docent de la Universitat Oberta de Catalunya.Material docente de la "Universitat Oberta de Catalunya".Learning material of the "Universitat Oberta de Catalunya"

Application Acceleration on FPGAs with OmpSs@FPGA

© 2019 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes,creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works.OmpSs@FPGA is the flavor of OmpSs that allows offloading application functionality to FPGAs. Similarly to OpenMP, it is based on compiler directives. While the OpenMP specification also includes support for heterogeneous execution, we use OmpSs and OmpSs@FPGA as prototype implementation to develop new ideas for OpenMP. OmpSs@FPGA implements the tasking model with runtime support to automatically exploit all SMP and FPGA resources available in the execution platform. In this paper, we present the OmpSs@FPGA ecosystem, based on the Mercurium compiler and the Nanos++ runtime system. We show how the applications are transformed to run on the SMP cores and the FPGA. The application kernels defined as tasks to be accelerated, using the OmpSs directives are: 1) transformed by the compiler into kernels connected with the proper synchronization and communication ports, 2) extracted to intermediate files, 3) compiled through the FPGA vendor HLS tool, and 4) used to configure the FPGA. Our Nanos++ runtime system schedules the application tasks on the platform, being able to use the SMP cores and the FPGA accelerators at the same time. We present the evaluation of the OmpSs@FPGA environment with the Matrix Multiplication, Cholesky and N-Body benchmarks, showing the internal details of the execution, and the performance obtained on a Zynq Ultrascale+ MPSoC (up to 128x). The source code uses OmpSs@FPGA annotations and different Vivado HLS optimization directives are applied for acceleration.This work is partially supported by the European Union H2020 program through the EuroEXA project (grant 754337), and HiPEAC (GA 687698), by the Spanish Government through Programa Severo Ochoa (SEV-2015- 0493), by the Spanish Ministry of Science and Technology (TIN2015-65316-P) and the Departament d’Innovació Universitats i Empresa de la Generalitat de Catalunya, under project MPEXPAR: Models de Programació i Entorns d’Execució Paral·lels (2014-SGR-1051).Peer Reviewe

Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study

The aim of this study was to know the prevalence and severity of COVID-19 in patients treated with long-term macrolides and to describe the factors associated with worse outcomes. A cross-sectional study was conducted in Primary Care setting. Patients with macrolides dispensed continuously from 1 October 2019 to 31 March 2020, were considered. Main outcome: diagnosis of coronavirus disease-19 (COVID-19). Secondary outcomes: symptoms, severity, characteristics of patients, comorbidities, concomitant treatments. A total of 3057 patients met the inclusion criteria. Median age: 73 (64–81) years; 55% were men; 62% smokers/ex-smokers; 56% obese/overweight. Overall, 95% of patients had chronic respiratory diseases and four comorbidities as a median. Prevalence of COVID-19: 4.8%. This was in accordance with official data during the first wave of the pandemic. The most common symptoms were respiratory: shortness of breath, cough, and pneumonia. Additionally, 53% percent of patients had mild/moderate symptoms, 28% required hospital admission, and 19% died with COVID-19. The percentage of patients hospitalized and deaths were 2.6 and 5.8 times higher, respectively, in the COVID-19 group (p < 0.001). There was no evidence of a beneficial effect of long-term courses of macrolides in preventing SARS-CoV-2 infection or the progression to worse outcomes in old patients with underlying chronic respiratory diseases and a high burden of comorbidity